5 Key Sessions, Interviews at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharmacy Times will be covering the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which gathers pharmacy professionals working in malignant and classical hematology in New Orleans, Louisiana.

Pharmacy Times will be covering the 64th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans, Louisiana from December 10 to 13, 2022.

The ASH Annual Meeting and Exposition brings together pharmacy professionals working in malignant and classical hematology from across the country for scientific symposia, educational sessions, scientific workshops, trainee activities, poster walks, and abstract presentations aimed at supporting decisions regarding diagnostic and treatment options through a systematic review of the best available evidence. Specifically, the 64th ASH Annual Meeting and Exposition will cover topics on disease states such as sickle cell disease, venous thromboembolism, anticoagulation in patients with COVID-19, immune thrombocytopenia, Von Willebrand disease, and acute myeloid leukemia.

Pharmacy Times’ coverage of the 64th ASH Annual Meeting and Exposition sessions will include:

  • Commentary and insights from Cynthia Dunbar, MD, a National Institutes of Health (NIH) distinguished investigator at the National Heart, Lung, and Blood Institute of the NIH, on a late-breaking abstract covering the open-label, phase 3, randomized controlled ALIFE 2 trial. Based on the trial results, the investigators noted that they do not advise the routine use of low-molecular-weight heparin in women with recurrent pregnancy loss and confirmed inherited thrombophilia. Dunbar explained that in her view, this late-breaking abstract is the most interesting and practice-changing abstract at the ASH annual meeting for potentially the largest number of people.
  • On December 10, a presentation titled “Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study,” presents the efficacy and safety results with median 56 months (range, 25-68 months) follow-up (median 41 months post randomization) from the phase 2, multicenter CAPTIVATE study (NCT02910583) evaluating first-line Ibr plus Ven in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have indication for treatment.
  • An interview with Everett Meyer, MD, PhD, medical and scientific director of the Cellular Therapy Facility, Stanford Health Care and assistant professor of medicine, Blood and Marrow Transplantation, Stanford University, on their presentation titled “Rapid Immune Reconstitution and Elevated Regulatory T Cell Frequencies in Patients Treated with Orca-T,” which provides an overview of immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplant (MA-alloHSCT) in 100 adult patients who received a T-cell-depleted graft with additional infusion of conventional T cells and regulatory T cells (Orca-T), a high precision cell therapy currently being investigated for the treatment of certain hematological malignancies otherwise treated with MA-alloHSCT.
  • On December 11, a session on “Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN,” presents the patient-reported outcomes from the phase 2 GRIFFIN trial (NCT02874742) at the final study analysis after all patients had completed 1 year of follow-up post maintenance therapy with a median follow-up of 49.6 months.
  • And lastly, an interview with Frederick Locke, MD, medical oncologist and translational researcher, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, on a presentation titled “Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7.” Locke provides an analysis of the results of the ZUMA-7 trial regarding the association of metabolic tumor volume and clinical outcomes, which showed that event-free survival was superior for axicabtagene ciloleucel (Yescarta; Kite Pharma, Inc) compared to standard-of-care for patients with high and low metabolic tumor volume.

Stay tuned on PharmacyTimes.com and follow Pharmacy Times on social media for exclusive, live coverage and the latest updates from the 64th ASH Annual Meeting and Exposition.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.